p16 promoter hypermethylation is associated with increased breast cancer risk

Wang,Li; Tang,Lin; Xie,Ruilian; Nie,Weiwei; Chen,Longbang; Guan,Xiaoxiang

doi:10.3892/mmr.2012.1001

p16 promoter hypermethylation is associated with increased breast cancer risk

Authors:
- Li Wang
- Lin Tang
- Ruilian Xie
- Weiwei Nie
- Longbang Chen
- Xiaoxiang Guan
View Affiliations

Affiliations: Department of Medical Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, P.R. China
Published online on: July 23, 2012 https://doi.org/10.3892/mmr.2012.1001
Pages: 904-908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to investigate the effects of p16 hypermethylation on breast cancer quantitatively through a meta-analysis of available case-control studies (including malignant, benign and normal breast cancer tissues). The PubMed, Web of Science and EBSCO databases were searched from their inceptions to February 1, 2012. Crude odds ratios (ORs) with 95% conﬁdence intervals (CIs) were extracted and pooled to assess the strength of the association between p16 hypermethylation and breast cancer risk. A total of eight studies, including 691 breast cancer cases and 525 control cases, were identified for meta-analysis. Statistically significant ORs of p16 hypermethylation were obtained from the breast cancer and control groups (OR, 6.58; 95% CI, 1.15‑37.75; P=0.03). However, no significant associations between the methylation and ER and PR status in breast cancer were detected (OR, 1.24; 95% CI, 0.64‑2.41; P=0.52; OR, 1.49; 95% CI, 0.81‑2.75; P=0.20, respectively). The meta-analysis indicated that p16 hypermethylation significantly increases breast cancer risk. However, no significant associations between the methylation and ER and PR status in breast cancer were detected.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar
2	Tao MH, Shields PG, Nie J, et al: DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 114:559–568. 2009. View Article : Google Scholar : PubMed/NCBI
3	Holst CR, Nuovo GJ, Esteller M, et al: Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63:1596–1601. 2003.PubMed/NCBI
4	Tlsty TD, Crawford YG, Holst CR, et al: Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia. 9:263–274. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wajed SA, Laird PW and DeMeester TR: DNA methylation: An alternative pathway to cancer. Annals Surg. 234:10–20. 2001. View Article : Google Scholar : PubMed/NCBI
6	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis - epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
7	Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.PubMed/NCBI
8	Di Vinci A, Perdelli L, Banelli B, et al: p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer. 114:414–421. 2005.PubMed/NCBI
9	Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B and Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 160:605–612. 2002. View Article : Google Scholar : PubMed/NCBI
10	Cavusoglu AC, Sevinc AI, Saydam S, et al: Promoter methylation and expression changes of CDH1 and P16 genes in invasive breast cancer and adjacent normal breast tissue. Neoplasma. 57:465–472. 2010. View Article : Google Scholar : PubMed/NCBI
11	Jing F, Jun L, Yong Z, et al: Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology. 75:60–66. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jing F, Yuping W, Yong C, et al: CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol. 31:321–331. 2010. View Article : Google Scholar : PubMed/NCBI
13	Raish M, Dhillon VS, Ahmad A, et al: Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol. 2:264–270. 2009. View Article : Google Scholar
14	Vallian S, Sedaghat M, Nassiri I and Frazmand A: Methylation status of p16 (INK4A) tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol. 135:991–996. 2009. View Article : Google Scholar : PubMed/NCBI
15	Van Zee KJ, Calvano JE and Bisogna M: Hypomethylation and increased gene expression of p16(INK4a) in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene. 16:2723–2727. 1998.PubMed/NCBI
16	Woodcock DM, Linsenmeyer ME, Doherty JP and Warren WD: DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer. 79:251–256. 1999. View Article : Google Scholar : PubMed/NCBI
17	Moher D, Liberati A, Tetzlaff J, Altman DG and Grp P: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Reprinted from Annals of Internal Medicine). Physical Therapy. 89:873–880. 2009.
18	Bero L and Rennie D: The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health-care. JAMA. 274:1935–1938. 1995. View Article : Google Scholar : PubMed/NCBI
19	Higgins JPT, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
20	Jing F, Zhang J, Tao J, et al: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3 sigma in serum of sporadic breast cancer patients. Onkologie. 30:14–19. 2007. View Article : Google Scholar : PubMed/NCBI
21	Li SY, Rong MN and Iacopetta B: DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett. 237:272–280. 2006. View Article : Google Scholar : PubMed/NCBI
22	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
23	Yang X, Yan L and Davidson NE: DNA methylation in breast cancer. Endocr Relat Cancer. 8:115–127. 2001. View Article : Google Scholar
24	Szyf M, Pakneshan P and Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol. 68:1187–1197. 2004. View Article : Google Scholar : PubMed/NCBI
25	Rocco JW and Sidransky D: p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 264:42–55. 2001. View Article : Google Scholar : PubMed/NCBI
26	Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
27	McDermott KM, Zhang JM, Holst CR, Kozakiewicz BK, Singla V and Tlsty TD: p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol. 4:350–365. 2006. View Article : Google Scholar : PubMed/NCBI
28	Bender CM, Pao MM and Jones PA: Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:95–101. 1998.
29	Zhang B, Huang T, Liu K, Chen J and Wang G: Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene. J Huazhong Univ of Sci Technology Med Sci. 27:543–546. 2007. View Article : Google Scholar : PubMed/NCBI
30	David GL, Yegnasubramanian S, Kumar A, et al: MDR1 promoter hypermethylation in MCF7 human breast cancer cells - Changes in chromatin structure induced by treatment with 5-aza-cytidine. Cancer Biol Ther. 3:540–548. 2004. View Article : Google Scholar : PubMed/NCBI